1. Home
  2. AGEN vs TMQ Comparison

AGEN vs TMQ Comparison

Compare AGEN & TMQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGEN
  • TMQ
  • Stock Information
  • Founded
  • AGEN 1994
  • TMQ 2004
  • Country
  • AGEN United States
  • TMQ Canada
  • Employees
  • AGEN N/A
  • TMQ N/A
  • Industry
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • TMQ Precious Metals
  • Sector
  • AGEN Health Care
  • TMQ Basic Materials
  • Exchange
  • AGEN Nasdaq
  • TMQ Nasdaq
  • Market Cap
  • AGEN 96.2M
  • TMQ 83.6M
  • IPO Year
  • AGEN 2000
  • TMQ N/A
  • Fundamental
  • Price
  • AGEN $2.83
  • TMQ $1.11
  • Analyst Decision
  • AGEN Buy
  • TMQ
  • Analyst Count
  • AGEN 3
  • TMQ 0
  • Target Price
  • AGEN $10.50
  • TMQ N/A
  • AVG Volume (30 Days)
  • AGEN 566.5K
  • TMQ 390.9K
  • Earning Date
  • AGEN 11-12-2024
  • TMQ 02-07-2025
  • Dividend Yield
  • AGEN N/A
  • TMQ N/A
  • EPS Growth
  • AGEN N/A
  • TMQ N/A
  • EPS
  • AGEN N/A
  • TMQ N/A
  • Revenue
  • AGEN $160,427,000.00
  • TMQ N/A
  • Revenue This Year
  • AGEN N/A
  • TMQ N/A
  • Revenue Next Year
  • AGEN $36.13
  • TMQ N/A
  • P/E Ratio
  • AGEN N/A
  • TMQ N/A
  • Revenue Growth
  • AGEN 59.00
  • TMQ N/A
  • 52 Week Low
  • AGEN $2.50
  • TMQ $0.25
  • 52 Week High
  • AGEN $19.69
  • TMQ $1.40
  • Technical
  • Relative Strength Index (RSI)
  • AGEN 39.40
  • TMQ 52.35
  • Support Level
  • AGEN $2.65
  • TMQ $1.10
  • Resistance Level
  • AGEN $3.85
  • TMQ $1.20
  • Average True Range (ATR)
  • AGEN 0.29
  • TMQ 0.08
  • MACD
  • AGEN -0.02
  • TMQ -0.02
  • Stochastic Oscillator
  • AGEN 15.00
  • TMQ 54.76

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-lead-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

Share on Social Networks: